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Abstract 
Lassa fever (LF) is a devastating viral disease prevalent in West Africa. Efforts to take on this 
public  health  crisis  have  been  hindered  by  lack  of  infrastructure  and  rapid  field  deployable 
diagnosis in areas where the disease is prevalent.   Recent capacity building at the Kenema 
Government Hospital Lassa Fever Ward (KGH LFW) in Sierra Leone has lead to a major turning 
point in the diagnosis, treatment and study of LF. Herein we present the first comprehensive 
rapid diagnosis and real time characterization of an acute hemorrhagic LF case at KGH LFW. 
This  case  report  focuses  on  a  third  trimester  pregnant  Sierra  Leonean  woman  from  the 
historically non-endemic Northern district of Tonkolili who survived the illness despite fetal 
demise.  
Employed in this study were newly developed recombinant LASV Antigen Rapid Test cassettes 
and dipstick lateral flow immunoassays (LFI) that enabled the diagnosis of LF within twenty 
minutes of sample collection. Deregulation of overall homeostasis, significant hepatic and renal 
system involvement, and immunity profiles were extensively characterized during the course of 
hospitalization.  Rapid  diagnosis,  prompt  treatment  with  a  full  course  of  intravenous  (IV) 
ribavirin, IV fluids management, and real time monitoring of clinical parameters resulted in a 
positive maternal outcome despite admission to the LFW seven days post onset of symptoms, 
fetal  demise,  and  a  natural  still  birth  delivery.  These  studies  solidify  the  growing  rapid 
diagnostic, treatment, and surveillance capabilities at the KGH LF Laboratory, and the potential 
to significantly improve the current high mortality rate caused by LF.  As a result of the growing 
capacity, we were also able to isolate Lassa virus (LASV) RNA from the patient and perform 
Sanger sequencing where we found significant genetic divergence from commonly circulating 
Sierra Leonean strains, showing potential for the discovery of a newly emerged LASV strain  
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with expanded geographic distribution. Furthermore, recent emergence of LF cases in Northern 
Sierra Leone highlights the need for superior diagnostics to aid in the monitoring of LASV strain 
divergence with potentially increased geographic expansion.  
5 
 
Background 
LASV, a member of the Arenaviridae family, is the etiologic agent of LF, which is an 
acute and often fatal illness endemic to West Africa.  There are an estimated 300,000- 500,000 
cases of LF each year [1-3] with a mortality rate of 15%-20% for hospitalized patients, which 
can become as high as 50% during epidemics [4,5] and ~90% in third trimester pregnancies for 
both  expectant  mother  and  fetus.    Presently,  there  is  no  licensed  vaccine  or  immunotherapy 
available for prevention or treatment of this disease. The severity of the disease, its ability to be 
transmitted  by  aerosol  droplets,  and  the  lack  of  a  vaccine  or  therapeutic  drug  led  to  its 
classification as a National Institutes of Allergy and Infectious Diseases (NIAID) Category A 
pathogen and biosafety level-4 (BSL-4) agent.  Several imported LF cases have been described 
since 1973, primarily from foreign nationals displaying signs of the disease upon returning to 
native countries or having been evacuated after falling ill abroad [6-32]. 
While  there  is  no  approved  therapeutic  for  LF,  the  antiviral  drug  ribavirin  has  been 
demonstrated to reduce fatality from 55% to 5%, but only if administered within 6 days of the 
onset of symptoms [33,34]. The requirement for the drug to be administered at an early stage of 
infection to successfully alter disease outcome limits its utility given that LF has an indolent 
course and is difficult to diagnose by symptoms alone, particularly in the early stages where 
ribavirin is most effective.  There is no commercially available LF diagnostic assay, which is a 
major challenge to early detection and rapid implementation of existing treatment regimens.  
Despite the devastating effects of LF in Western African nations, to date, resources have 
not historically been available for the diagnosis, treatment, and monitoring of patients in country. 
Continuous infrastructure improvements at the KGH LFL by Tulane University, the Department 
of  Defense  (Dodd),  and  the  United  States  Army  Medical  Research  Institute  of  Infectious  
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Diseases  (USAMRIID)  since  2005  have  resulted  in  the  implementation  of  sophisticated 
diagnostic and research capabilities at the site.  Currently, the KGH LFL diagnoses LF using 
ELISA and LFI that detect viral antigen (Ag), and virus-specific IgM and IgG levels in the serum 
of every suspected case admitted to the KGH LFW.  Additionally, the laboratory assesses 14 
serum  analyses  using  a  Piccolo
®  blood  chemistry  analyzer  coupled  with  comprehensive 
metabolic panel disks.  Flow cytometry powered by a 4-color Accrue
® C6 cytometer performs 
immunophenotyping, intracellular and bead-based secreted cytokine analysis.  The laboratory 
produces its own electricity via a state-of-the-art solar collection and power generation array 
funded by a Coypu Foundation (New Orleans, LA, U.S.A.) grant awarded to Tulane University, 
and installed by South Coast Solar, L.L.C. (Metairie, LA, U.S.A.).  Together, these capabilities 
facilitated the analysis of metabolic and inflammatory functions in real time utilizing the sera of 
individuals  discussed  in  this  case  report  with  concomitant,  appropriate  medical  intervention.  
Subsequently, LASV sequences amplified onsite from the serum of the afflicted LF patient were 
partially  characterized  and  seemingly  identified  a  new,  significantly  divergent  variant  of  the 
virus from commonly circulating Sierra Leonean strains. 
The case, a third trimester pregnant woman with acute hemorrhagic LF, discussed herein 
was closely monitored for 13 days during her hospitalization. During this period, her condition 
stabilized, she delivered a stillborn fetus, began walking with supervision, completed ribavirin 
treatment,  and  was  awaiting  discharge  pending  improved  overall  health.    These  studies 
contributed  to  a  better  understanding  of  the  importance  of  and  advancement  in  real  time 
diagnosis  and  management  of  Lassa  hemorrhagic  fever  in  resource  poor,  endemic  areas  of 
Western  Africa,  particularly  in  the  most  highly  affected  subset  of  patients  afflicted  by  this 
disease - late stage pregnant women and their fetuses.    
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Methods 
Objectives 
This study aimed to characterize a hospitalized acute LF case from onset of diagnosis to 
near full recovery using advanced rapid diagnostics and state-of-the-art technologies to dissect 
immune and metabolic responses in real time at the KGH LFL in Sierra Leone. 
Human Subjects 
Suspected LF patients, close contacts, and healthy volunteers were eligible to participate 
in these studies as outlined in Tulane University’s Institutional Review Board (IRB) protocol for 
this project, National Institutes of Health/ National Institutes of Allergy and Infectious Diseases 
guidelines  governing  the  use  of  human  subject  for  research,  and  Department  of  Health  and 
Human  Services/  National  Institutes  of  Health/  National  Institute  of  Allergy  and  Infectious 
Diseases Challenge and Partnership Grant Numbers AI067188 and AI082119.  This project was 
approved by the Tulane University IRB.  The patients in this manuscript have given written 
informed consent to the publication of their case details.  Patient G-1442 consented to have 
photographs  taken  at  the  time  of  admission  and  was  informed  that  they  may  be  used  for 
illustrative purposes in scientific publications. 
Sera from suspected LF patients and healthy volunteers  
Small blood volumes, typically five milliliters (mL) for serum separation and two mL 
uncoagulated sample were collected daily from patient G-1442, with consent from the attending 
physician (Donald S. Grant, M.D.), except on day nineteen.  A serum sample obtained from a 20-
year old pregnant woman who succumbed to LF at the KGH Maternity Ward on August 29, 
2010 was used as positive control. A single sample was collected from this subject before her  
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expiration and assigned the coded designation G-1177.  Four additional sera from patients who 
succumbed to LF at the KGH LFW between September and December 2010 were also partially 
characterized (G-1209, G-1220, G-1380, and G-1401).  One close contact of G-1442 was tested 
for Ag, IgM, and IgG and assigned the coded designation G-1446. Finally sera from healthy 
Sierra Leonean volunteers were used as normal controls, and assigned the coded designations 
LS0xx. Blood was collected in serum vacutainer tubes from patients and control donors and 
allowed to coagulate for 20 minutes at room temperature.  Serum was separated from coagulated 
blood by centrifugation.  The serum fraction was collected for analysis and aliquots were stored 
in cryovials at -20
oC. 
Detection of LASV antigen by LFI diagnostic and ELISA 
Serum  levels  of  LASV  nucleoprotein  (NP)-specific  Ag  were  initially  measured  using 
LASV Antigen Rapid Test cassettes and dipstick LFI currently under pre-clinical development 
by  Corgenix  Medical  Corp.,  Broomfield,  CO,  U.S.A.  and  the  Viral  Hemorrhagic  Fever 
Consortium (see acknowledgements).  Both Rapid Test strip designs utilize two NP specific 
murine monoclonal antibodies (Autoimmune Technologies, L.L.C., New Orleans, LA, U.S.A.) in 
a  capture  and  gold-conjugated  detection  format.  An  anti-murine  IgG  polyclonal  antibody  is 
included as a control line. The LASV Antigen Rapid Test cassettes can detect LASV NP in 
serum and plasma.  Twenty five µL of sample were added to the sample well then chased with 
100  µL  of  buffer.    Strong  titers  could  be  detected  as  early  as  5  minutes  but  final  visual 
interpretation was conducted between 15-25 minutes of development time. The LASV Antigen 
Rapid  Test  dipsticks  are  similar  in  construction  to  the  LFI  but  include  a  plasma  separation 
sample pad.  Whole blood from a finger stick or blood collection tubes (EDTA, citrate) was  
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diluted 1:3 with sample buffer in a test tube followed by addition of LASV Antigen Rapid Test 
dipsticks.  Alternatively, one drop of whole blood was added directly to the sample pad, and 
once the whole blood absorbed into the plasma separator material, the dipstick was placed in a 
test tube containing chase buffer to initiate strip development. In this format strong titers could 
also be detected as early as 5 minutes but final visual interpretation was conducted between 15-
25 minutes of development time.  Results were recorded photographically and reflectance scans 
were taken with a QIAGEN ESE-Quant GOLD LFI reader (QIAGEN GmbH, Hilden, Germany).  
Test line reflectance and Test to Control ratios (T/C Ratio) were calculated for each sample, and 
compared  to  a  curve  generated  with  recombinant  quantified  NP  spiked  into  normal  human 
serum.  
The positive LF diagnosis was then confirmed with a sensitive antigen-capture ELISA 
employing either  a murine monoclonal or caprine polyclonal capture antibody (Autoimmune 
Technologies,  L.L.C.,  New  Orleans,  LA,  U.S.A.)  followed  by  a  peroxidase-labeled  caprine 
reagent and tetramethylbenzidine (TMB) substrate.  Capture antibodies were coated in stripwell 
plates,  blocked,  dried,  and  packaged  with  desiccating  packs  (Corgenix  Medical  Corp.).  A 
standard curve was generated with recombinant LASV NP for quantitation of serum levels of 
virus-associated nucleoprotein by ELISA.  Sera from previously confirmed LF cases were used 
as positive controls.  Sera from healthy Sierra Leonean and normal U.S. sera panels were used as 
negative controls.  For analysis, sera were diluted 1:10 and incubated in wells for 60 minutes at 
37°C, washed, followed by incubation with optimized HRP-labeled anti-LASV NP conjugates 
for an additional 30 minutes.  After washing, detection was performed with TMB substrate for 
15 minutes at room temperature, stopped with sulfuric acid, and read at A450 in a BioTek ELISA  
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plate reader (BioTek, Winooski, VT, U.S.A.).  The generation of recombinant full length LASV 
NP has been described elsewhere [35]. 
Detection of LASV-specific serum IgM and IgG levels by ELISA  
Individual  recombinant  LASV  proteins  (Vybion,  Inc.,  Ithaca,  NY,  U.S.A.)  and 
combinations optimized for detection of virus-specific IgM and IgG levels in serum were coated 
in stripwell plates, as outlined above.  The generation of recombinant mammalian cell-expressed 
full  length  LASV  GP1  and  GP2  have  been  described  elsewhere  [36].
  Bacterially-expressed 
LASV Z matrix protein was kindly provided by Dr. Erica O. Saphire, The Scripps Institute, La 
Jolla, CA, U.S.A.  Sera from suspect and convalescent LF cases previously characterized for 
LASV  antigen-specific  IgM  and  IgG  responses  were  used  as  positive  controls  in  respective 
ELISA formats.  Sera from healthy Sierra Leonean volunteers without significant titers against 
LASV antigens, and normal U.S. sera panels were used as negative controls.  For analysis, sera 
were diluted 1:100 and incubated in wells for 30 minutes at room temperature, washed, followed 
by incubation with optimized HRP-labeled anti-human IgG or IgM conjugates for an additional 
30 minutes.  After washing, detection was performed with TMB substrate for 10 minutes at room 
temperature, and read as described above. 
Comprehensive Metabolic Panel analysis  
The  kinetics  of  fourteen  serum  analyses  were  analyzed  daily  using  a  Piccolo
®  blood 
chemistry  analyzer  (Abaxis,  Inc.,  Union  City,  CA,  U.S.A.)  with  Comprehensive  Metabolic 
Reagent Discs, as per manufacturer’s recommendations.   
Cytokine kinetics   
11 
 
Kinetics  of  eleven  serum  cytokines  were  analyzed  with  an  Accrue  C6
®  benchtop 
cytometer (Accrue Cytometers Inc., Ann Harbor, MI, U.S.A.) and an eBioscience FlowCytomix 
Human Th1/Th2 11-plex Kit (Bender MedSystems GmbH, Vienna, Austria).  Serum aliquots 
collected and frozen throughout the timeline were analyzed concurrently at the end of the study. 
Urinalysis  
Ten separate urinalysis tests were performed daily within 20 minutes of urine collection, 
except for the last two days of this study timeline, using a VWR
® Urine Reagent Strips (VWR, 
Arlington Heights, IL, U.S.A.). 
qPCR  
RNA was extracted from serum using QIAmp Viral RNA Mini kit (QIAGEN, Valencia, 
CA, U.S.A.). RT-PCR was performed using SuperScript III (Invitrogen, Carlsbad, CA, U.S.A.) 
and qPCR was performed with PerfeCTa SYBR Green (Quanta Biosciences, Gaithersburg, MD, 
U.S.A.) using primers 36E2 and 80F2 directed against the LASV GPC gene [37].  A seed stock 
of Josiah LASV strain (kindly provided by Dr. Lisa E. Hensley, Viral Therapeutics Branch, 
Virology Division, USAMRIID Diagnostic Systems Division, Fort Detrick, MD, U.S.A.) was 
used as a standard for calculating RNA copies of LASV present in the serum samples. 
Sequencing and phylogenetic analyses  
The  entire  LASV  S  segment  was  amplified  using  primer 
CGCACAGTGGATCCTAGGCAT.  Standard  Sanger  sequencing  was  then  performed  using 
primer G2 targeting the glycoprotein complex (GPC) gene [38]. Alignments from patient G-1442 
and 73 partial GPC sequences were created using Muscle [39] followed by manual adjustments.  
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A Neighbor-joining tree was created using LASV Pinneo as an outgroup, and bootstrapped over 
1000 replicates. 
Statistical methods  
ELISA data were plotted in MS Excel as mean±SD, N=2, with error bars.  Analysis 
between time points was performed with Analysis of Variance (ANOVA).  Cytokine levels were 
calculated by curve fitting analysis of data generated with quantified standards for each analyte.   
 
Results 
Case presentation 
On January 20
th, 2011 the KGH Maternity Ward alerted the LF team of a suspected case 
from Tongo, lower Bambara chiefdom in Kenema district, Sierra Leone.  A blood sample was 
collected and sent to the KGH LFL for testing.   LASV NP antigen LFI diagnostic confirmed LF 
within 20 minutes of sample processing (Figure 1).  The patient was a 22-year old pregnant 
woman, estimated gestational age 32 weeks, who had recently travelled to Tongo from Mabineh 
1 village, Kunike chiefdom, Tonkolili district, northern Sierra Leone (Additional File 1, Figure 
1).  She arrived in Tongo on January 10
th experiencing fever and lower abdominal pain.  She was 
taken to Tongo Maternal Health Post on January 15
th for observation where she was referred to 
KGH on January 19
th as a maternity case after failing to respond to treatment with antibiotics 
(Ampicillin and Gentamycin).  The KGH Maternity Ward staff suspected LF upon arrival and 
referred the case to the LFW and LFL. This patient was assigned the coded designation G-1442, 
which will be used henceforth.  
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Case  G-1442  presented  with  symptoms  of  fever,  sore  throat,  headache,  red  eyes, 
weakness, facial edema, retrosternal pain, generalized abdominal pain, epistaxis and haemoptysis 
(Additional File 2, Figure 2).  On examination, her body temperature was 36.5
oC, pulse rate of 
96 beats/minute, respiration rate of 26/min, and blood pressure of 90/40 mm Hg (Additional File 
3, Figure 3).  Respiratory findings included nasal flaring and bibasal crepitations.  Abdominal 
findings included a hard uterus that was tender to palpation with an estimated symphysis fundal 
height of 30-32 weeks. There was marked epigastric tenderness.  Minute bilateral conjunctival 
hemorrhages were also noted.  The differential diagnosis included probable LF, pneumonia, and 
a possible concealed antepartum hemorrhage (concealed placental abruption).   
Travel history and contact tracing  
The case patient had travelled from Mabineh 1 to Waterloo (south of Freetown) three 
weeks  prior  to  her  illness.    Upon  returning  from  Waterloo  she  resided  in  Massingbi  (a 
neighboring town to Mabineh 1) for one week before returning to Mabineh 1.  She remained in 
Mabineh 1 for five days before departing for Tongo.  According to relatives it is estimated that 
the case patient left Mabineh 1 between January 6
th and 8
th bound for Tongo (Additional File 1, 
Figure 1.C).  She had no known exposure to an ex-LF patient or contact with rodents prior to her 
illness.  However, an assessment of her previous dwelling in Mabineh 1 revealed evidence of 
rodent waste, and rat holes in a structure constructed with mud and with large open spaces in 
walls.  The patient had not been seen by a medical professional throughout her pregnancy as 
nurses at the Mabineh Health Post could not account for her visiting the center at anytime over 
the previous eight months.  The date of onset of LF was recorded as January 13
th, with fever, 
headache, and lower abdominal pain, after failure to respond to treatment with anti-malarials.   
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The patient tested positive for malaria parasites while in Tongo (verbal communication).  The 
conclusion from the investigation conducted by the LF outreach team points to infection with 
LASV in the northern towns of Massingbi and Mabineh 1 where the case patient resided during 
most of the early stage of the incubation period of the disease.   
Contacts of the case patient were identified and none have developed symptoms of LF to 
date.  All contacts were monitored throughout the incubation period (21 days) from date of last 
reported exposure.  Contacts were family members from Mabineh 1, nursing staff at the health 
clinic in Tongo, and the patient’s brother who resides in Tongo township.  The brother of G-
1442, designated G-1446, with whom she resided while in Tongo, accompanied her to the KGH 
and was tested for LASV antigen, IgM, and IgG.  He tested negative for all three (Figure 2).  
Testing of G-1446 was prompted by his close contact with G-1442 in Tongo for 9 days, and 
given the hemorrhagic presentation, with vomiting by the latter at the time of admission to KGH.  
Additionally, G-1442’s mother traveled from Mabineh 1 to Kenema to assist with her daughter’s 
care during hospitalization at the KGH LFW.  The mother did not develop a fever and did not 
feel ill at any time over the course of nearly two weeks of permanence in Kenema; therefore, she 
was  not  tested  for  LASV  antigen  or  immunoglobulin  levels.    The  patient  revealed  that  she 
travelled from Masingbi to Tongo by motorcycle over the course of 2 days.  The motorcycle 
operator was an unidentified male, and further information on his whereabouts and health status 
is not known. 
The geographical location where G-1442 contracted LF is of particular importance.  In 
recent  months  several  cases  have  been  identified  by  our  field  research  team  in  the  northern 
districts  of  Bombali  and  Tonkolili  (Additional  File  1,  Figure  1.A),  which  have  not  been 
previously considered endemic regions for the illness.  Since the Fall of 2010, however, two  
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cases of severe hemorrhagic LF have been identified in these two northern districts, both with 
fatal outcomes.  In addition, several other LF cases from the same districts have been confirmed 
with subsequent treatment at the KGH LFW and positive outcomes.  During the preparation of 
this manuscript, additional LF cases had been diagnosed at the Magbeneth Hospital in Makeni 
using LASV Ag Rapid LFI diagnostics provided by Tulane University and Corgenix Medical 
Corporation.  
Diagnostic Analysis 
A blood specimen collected on patient G-1442’s day of admission was positive for LASV 
NP Ag by LFI diagnostic (Figure 1), and by quantitative NP capture ELISA, with a level of 
2.265  g/mL NP (Figure 2).  The LFI platform confirmed acute LF within 20 minutes of sample 
collection. IgM levels to recombinant LASV proteins (NP, GP1, GP2, Z) were determined by 
ELISA, with low but detectable levels of immunoglobulin to NP and Z (Figure 2B). This data 
suggests the patient was naive to LASV exposure prior to this incident. Statistically significant 
levels of low IgM response to GP1 and GP2 were detected on days 11-20 when compared to 
naïve negative controls and G-1142 sera from days 7 - 10 (p < 0.05) (Figure 2B).  Low levels of 
NP-specific IgG were not detected until at least day 12 post onset of illness (Figure 2C).  During 
the monitoring period G-1442 did not develop significant IgG titers against GP1, GP2, and Z.  
LASV NP antigen dropped rapidly over 3 days following treatment with ribavirin, and 
was below the limit of detection (LOD) of the assay by day 10 in an NP Ag capture ELISA 
(Figure 2A).  RNA was isolated from serum on the day of collection and analyzed by qPCR for 
amplification of a conserved 300 nt segment of the LASV GPC gene.   PCR confirmed and 
detected viral RNA in serum samples at least 2 days beyond the NP Ag ELISA (Figure 3).  
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Overall, the NP Ag capture ELISA, LFI diagnostic, and qPCR assay showed the same trend with 
decreasing titers of LASV following the start of ribavirin treatment. 
Clinical Chemistry  
On presentation to KGH LFW, the liver function panel revealed highly elevated levels of 
aspartate aminotransferase (AST) >2000 U/L, alanine transaminase (ALT) of 643 U/L, alkaline 
phosphatase (ALP) of 541 U/L, and total bilirubin (TBIL) of 35 micromoles per liter ( M/L)  
(2.05  mg/dL)  (Figure  4).    Levels  of  sodium,  potassium,  chloride,  calcium,  carbon  dioxide 
(TCO2), blood urea nitrogen (BUN), and total protein were within or near normal levels, and 
albumin was below normal range (Additional File 4, Figure 4).  At presentation the hemoglobin 
level (Hb) was 12.7 g/dL (Figure 4).   
Treatment and hospital course  
Intravenous ribavirin was administered upon NP Ag positive diagnosis by LFI: a loading 
dose of 30mg/kg followed by 15mg/kg every six hours for four days, followed by 7.5mg/kg 
every eight hours for six days. Amoxicillin, intravenous quinine in 5% dextrose, acetaminophen, 
and  routine  vitamins  (multivitamin,  ferrous  sulphate,  folic  acid)  were  commenced  upon 
admission to KGH. Patient G-1442 developed bleeding from the oral mucosa on day eight which 
resolved on day ten. On day ten she was much improved and was able to stand unaided.  Fetal 
demise  was  confirmed  with  the  aid  of  a  fetal  heart  Doppler  on  day  twelve.    She  had  an 
uncomplicated vaginal delivery of a stillborn fetus on day thirteen, at which time she was started 
on ampicillin and metronidazole. Artesunate was begun on day fifteen.  IV fluid boluses of five 
percent and 50% dextrose and Ringer’s Lactate solution were given as needed.    
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The sodium and chloride levels gradually decreased during the hospitalization period, 
following IV fluids management, and G-1442 remained hyponatremic between days 13 and 20 
and hypochloremic between days 16 and 20. Creatinine and BUN remained normal during her 
entire hospital stay resulting in a BUN:Cr ratio between 10 and 20 except for a transient increase 
to 24 on day 17 (Figure 4).  The ALT declined steadily during hospitalization, and was within 
normal levels on day 16 (42 U/L) and through the rest of the monitoring period, while the AST 
remained >2000 U/L for three days before declining to 100 U/L on day 20. The ALP remained 
elevated as well, decreasing to 259 U/L on day 20. The TBIL initially increased to 88  M/L  
(5.15 mg/dL), before dramatically declining two days after delivery (day 14) to 32 micromoles 
per liter (1.87 mg/dL).  Bilirubin continued to decrease over the remainder of the observation 
period, to within normal levels between days 16 and 20.  The Hb decreased from an initial 
normal level of 12.7 g/dL to between 10.4 and 11.1 g/dL throughout the hospitalization period 
(Figure 4B).  These Hb levels did not prompt the doctor to administer a blood transfusion. 
Cytokine profiles were performed on serum samples collected daily (Figure 5).  G-1442’s 
IFN-γ levels were highly elevated on the day of admission, but decreased to baseline levels by 
the following day and did not rise above normal levels over the ensuing 12 days of monitoring 
(Figure 5B).  A significant decrease in IL-6 and IL-10 levels was noted on day 8, but levels 
fluctuated throughout the course of hospitalization.  IL-8 levels dropped significantly on days 9 
and 10, followed by a spike on day 11, and a steady decrease thereafter.  TNF-β was present at 
elevated  levels  at  the  time  of  admission  and  decreased  to  near  background  levels  by  the 
following  day,  but  increased  significantly  and  steadily  throughout  the  hospitalization  period.  
Interleukins -1β, -2, -4, -5, 12p70, and TNF-α were not detected or were present in the serum of 
G-1442 at very low levels at all time points analyzed.  On day 20, the last day of monitoring, all  
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cytokines with the exception of TNF-β were at or near normal levels.  Interleukin-8 and TNF-α 
were elevated in one healthy control serum (LS004) but were within normal levels in the other 
healthy control serum (LS022).  All other cytokines were at baseline levels in both control sera 
(Figure 5A, B). 
Urinalysis profile  
Urinalysis revealed ongoing proteinuria (30 mg/dL) that peaked on the day of delivery 
(300 mg/dL) and subsequently decreased (trace to 30 mg/dL). It is unclear whether proteinuria 
resulted  from  LASV  infection,  pregnancy,  or  a  combination  of  factors.  There  was  no 
hypertension to suggest a diagnosis of pre-eclampsia. The presence of large blood was noted on 
all urinalysis results. Microscopy was not performed to examine for red blood cells or casts.  
Bilirubin (small to large) was present prior to and including the day of delivery, after which time 
it was absent, consistent with resolving biliary obstruction as indicated by the decrease in serum 
TBIL levels and ALP. Leukocyte esterase was absent to trace presence prior to delivery, after 
which  time  small  to  moderate  results  were  noted.  Since  analysis  was  performed  on  catch 
specimens, the possibility of contamination from vaginal fluid after delivery cannot be excluded. 
Nitrites were positive on day 18. No symptoms of urinary tract infection were noted (Additional 
File 5, Table 1).  
Sequencing analysis and strain characterization 
In order to get a better idea of the geographical location of the isolated strain, a 800nt 
fragment of the GPC gene from the serum of patient G-1442 was sequenced and compared to 
other strains circulating in Sierra Leone and West Africa. Phylogenetic analysis showed that the 
LASV from patient G-1442 clustered with other strains from Sierra Leone, but was significantly  
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different  from all of them, forming its own sub-group (Figure 6). The  strain was only 89% 
identical  to  the  prototypical  Sierra  Leonean  LASV  Josiah  strain  at  the  nucleotide  level.  In 
comparison, we have found other currently circulating strains from Sierra Leone to be more than 
95% identical to Josiah (Figure 6 and data not shown). This suggest that a new strain of LASV 
may be responsible for the recent outbreak of LF in the North of Sierra Leone, although more 
complete sequencing studies are required to firmly establish this. 
Chemistries of healthy volunteers and five fatal cases of LF  
In order to establish the capabilities and reliability of the Piccolo
®, complete chemistries 
were  performed  on  blood  drawn  from  two  healthy  Sierra  Leonean  volunteers  as  well  as  on 
samples from five patients who succumbed to LF (Additional File 6, Table 2).  Patient G-1177’s 
metabolic  and  biochemical  characterization  was  described  in  detail  elsewhere  [40].    The 
chemistries  of  the  two  healthy  volunteers  were  in  the  normal  range  as  specified  by  the 
manufacturer (Abaxis, Inc.) (Additional File 6, Table 2).  
LF patients G-1209, G-1220, G-1380, G-1401, and G-1177 had extremely abnormal labs 
prior to expiration (Additional File 6, Table 2).  Along with dysregulated serum electrolytes, all 
subjects had a highly elevated liver panel, and, with the exception G-1380, all had elevated levels 
of  BUN.    Additionally,  all  subjects  had  low  serum  albumin  and  total  protein  levels.    The 
cytokine profiles between healthy volunteers and subjects who succumbed to LF were largely 
unremarkable, with the single exception of IL-10, which was recorded at elevated levels in all 
cases (Additional File 6, Table 2 and unpublished data). 
 
Discussion  
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LASV Ag Rapid Test detected acute LASV infection in G-1442 within 20 minutes of 
serum collection and processing  at the KGH  LFL (Figure 1).  The patient was immediately 
transferred from the KGH Maternity Ward to the LFW upon diagnosis, permitting isolation and 
appropriate medical intervention including IV ribavirin administration, currently the only drug 
used in viremic cases of LF.  LFI diagnostic detected LASV NP Ag on the first two days at the 
KGH LFW (Figure 1), whereas antigen capture ELISA diagnostic detected the protein in the 
serum of G-1442 for three days following admission (Figure 2A).  Quantitative PCR extended 
detection of LASV RNA sequences for two days beyond the limit of detection of LASV NP Ag 
ELISA, thus establishing a role for each platform from sensitive and rapid point of care LFI 
diagnostic to ultrasensitive and time extended qPCR detection of very low levels of arenaviral 
RNA in the blood.   
ELISA data suggest that patient G-1442 was naïve to infection as she presented with very 
low LASV-specific IgM to all viral proteins analyzed at 7 days after onset of symptoms; she then 
began showing a consistent increase in NP-specific IgM, and a low level IgM response against 
the glycoproteins starting on day 11, which continued through all days monitored. Only IgG to 
NP  developed  over  the  analysis  timeline  (Figure  2C).    The  predominant,  mature,  humoral 
response in LF is against the viral NP Ag [41-43, unpublished data]. 
The metabolic panel of G-1442 as well as a previously characterized severe hemorrhagic 
LF case, G-1180, who also survived [40], show important differences with patients who succumb 
to the disease. Despite hepatic and renal dysfunction during the course of LF infection, neither 
patient  developed  elevated  levels  of  serum  CRE,  which  are  usually  associated  with  a  poor 
outcome
 [18].  In G-1442 the BUN:Cr ratio remained within normal levels throughout (10-20:1), 
with the notable exception of day 17, when it rose above 20 (24.2).  These data suggest that in G- 
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1442  renal  function  was  not  significantly  affected  by  LF.    Conversely,  G-1177,  a  late  term 
pregnant woman diagnosed with LF in August 2010, succumbed to the disease with a CRE level 
of 818  mol/L and a BUN:Cr of 5.6 prior to expiring, which is indicative of significant intrarenal 
damage Additional File 6, Table 2]. Another significant discrepancy between the two pregnant 
LF cases was the measured levels of AST.  In G-1177 the single sample AST level was zero, 
whereas G-1442 had a highly elevated level of AST at the time of admission (>2,000 U/L), 
which rapidly resolved over the course of treatment (Figure 4).  Levels of AST are commonly 
highly elevated in LF cases, thus the undetectable level in G-1177 may have been indicative of 
severe liver failure near the time of expiry and not a representative hepatic metabolic state in late 
term pregnancies afflicted by LASV infection. Both surviving patients, G-1442 and G-1180, 
showed rapid resolution of severe hepatic dysregulation, measured by ALP, ALT, and AST, to 
within normal or near normal levels at the conclusion of ribavirin treatment.  
At the time of admission G-1442 presented with elevated serum levels of IFN-γ, IL-6, IL-
8, and TNF-β (Figure 5 A, B).  Elevated IFN-γ and IL-6 levels are common in non-lethal LF and 
other febrile illnesses alike, but are highly variable in fatal cases of LF [18, 44].  Elevated IL-8 
levels have been associated with positive outcomes in acute LF, but are also common in native 
Sierra Leonean healthy controls [44, unpublished data].  Spontaneous cytokine production in 
acutely ill and healthy persons living in endemic areas for Human Immunodeficiency Virus, 
Malaria, Yellow Fever, Dengue, and assorted parasitic infections, has been reported [45], thus 
prompting evaluation of such immunomodulatory molecules in the context of specific disease 
states.    Measurable  and  sustainable  levels  of  TNF-β  in  G-1442  are  a  distinguishing  feature 
among the LF cases characterized to date.  Detection of TNF-β in G-1442 but not in any of the  
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approximately 100 additional LF patients analyzed in our studies thus far (unpublished data) may 
represent  a  rare  immunological  response  to  the  febrile  illness,  may  be  associated  with  the 
pregnant status of this patient, may have manifested because of a response to a co-infecting 
pathogen,  or  may  be  a  combination  of  factors.    The  anti-inflammatory  cytokine  IL-10  was 
elevated in G-1442’s serum throughout the treatment period.  Interleukin-10, a stimulator of B 
cell maturation and antibody production, is commonly recorded in LF patients when IgM and 
IgG responses to LASV antigens emerge [18,44], irrespective of outcome.  Interleukin-1β was 
not detected in G-1442 throughout the course of recovery from LF.  This observation generally 
contrasts with previous LF studies showing that IL-1β was significantly elevated in non-fatal 
versus fatal LF and non-LF febrile illness, but not in healthy controls [44]. 
Patient  G-1442’s  test  results,  in  conjunction  with  those  obtained  for  G-1180  [40], 
strengthen the hypothesis, as previously proposed by others, that an imbalance between pro- and 
pre-inflammatory cytokines plays an important role in the development of Lassa hemorrhagic 
shock, with poor outcome [18, 44]. As observed with G-1180, the marked absence of TNF-α, a 
potent inducer of endothelial damage via apoptosis [46] and thrombocytopenia [47], throughout 
the monitored course of G-1442’s illness, suggests a regulated and effective immune response at 
play.  These studies also suggest that lack of specific physiological responses, e.g. elevated TNF-
α, serum CRE, and BUN levels, may be relevant, early predictors of outcome in hemorrhagic 
LF.    It  is  also  noteworthy  that  G-1442  did  not  present  with  high  core  temperature,  which 
remained at or below 36.5
oC throughout the acute phase of the illness despite a febrile diagnosis 
(Additional File 3, Figure 3) and high IFN-γ levels (Figure 5B).  Her body temperature then 
fluctuated between 36
oC and 37.5
oC from day 15 onward.  
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Together, these data strengthen the potential for increased positive outcomes in cases of 
severe  hemorrhagic  LF.    More  importantly,  it  outlines  the  possibility  of  adequate  disease 
management with positive outcome in third trimester pregnancies, particularly for the mother 
[48].    Despite  severe  and  prolonged  multi-organ  dysregulation,  pro-  and  anti-inflammatory 
cytokine up- and down-regulation, management of a 32 week-pregnancy, a stillbirth delivery, 
and overall poor health, patient G-1442 was recovering well on day 20 and was discharged on 
day 25.  A quick diagnosis of acute LF followed by prompt treatment with IV ribavirin, IV fluids 
management, maintenance of electrolyte balance to counter hypovolemia, hemorrhagic shock, 
malnutrition, and adequate control of secondary infections, even 7 days post onset of symptoms 
in a severe case of the illness, can meet with a positive outcome. 
Additionally, this study highlights the emergence of LF cases in the northern districts of 
Sierra Leone, where the disease has not been widely reported or identified.  Recent collaborative 
efforts with staff at the Magbeneth Hospital in Makeni includes beta-testing of LASV Ag Rapid 
Test LFI diagnostic modules, community sensitization, and prompt reporting of antigen positive 
LF diagnoses to the KGH LFW for patient transport, isolation, and treatment and may be a 
contributing factor to the elevated number of reported cases in northern Sierra Leonean districts. 
With promising new diagnostics, we are able to both enhance care of patients in the clinical 
setting and increase our understanding of the range and impact of this devastating disease.  The 
continuous capacity building at the KGH LFL also permits real time analysis of viral RNA levels 
by  qPCR,  cDNA  generation,  followed  by  high-throughput  next-generation  sequencing.  
Although  more  extensive  studies  will  be  required  before  confirming  the  emergence  of  new 
LASV strains, particularly in the historically non-endemic northern districts of Sierra Leone,  
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sequencing efforts in this case point to divergence of circulating strains throughout the country, 
with possible widening in geographical distribution.  
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Figure 1. Rapid diagnosis of acute LF virus infection by LFI in patient G-1442  
LFI  diagnostic  (A)  and  dipstick  (B)  tests  detected  LASV  NP  in  the  serum  of  suspected  LF 
patients.    After  15  minutes  of  development  the  results  were  recorded  photographically  and 
reflectance scans were taken as outlined in Methods.  A representative normal serum sample 
analysis from a Sierra Leonean donor (- ctrl) is shown for comparison.  Only the control line 
developed  with  this  serum  sample.    Conversely,  sera  from  G-1442  generated  a  detectable 
precipitate in the test line, indicative of LASV NP antigen.  The positive control (+ ctrl) was 
recombinant LASV NP diluted in sample buffer.  The LFI diagnostic and dipstick platforms 
detected NP antigen on days 7-8.  Days 9-12 show no detectable antigen in either format.  Test 
line reflectance and Test to Control ratios (T/C Ratio) are indicated below each test. 
 
Figure  2.  Nucleoprotein,  virus-specific  IgM  and  IgG  detection  by  ELISA  in  G-1442, 
normal, and contact G-1446 sera 
An Ag capture ELISA was used to detect LASV NP in patient sera (A).  LASV NP Ag was not 
detected in normal sera from Sierra Leonean origin, or in contact G-1446.  The level of LASV 
NP  Ag  [blue  diamond]  in  G-1442  dropped  significantly  during  the  first  3  days  of  ribavirin 
administration, and was undetectable by day 10.  LASV-specific IgM (B) and IgG (C) were 
assayed in a recombinant ELISA plate format, with individually coated NP, GP1 (sGP1), GP2 
(GPC TM),  or  Z  proteins.    One  Sierra  Leonean  serum  registered  a  high  IgG  titer  to  NP 
(NHS015), whereas the other had moderate IgM titers to NP (NHS023), but both were negative 
for  IgG  and  IgM  to  Z  and  glycoproteins.  NP-specific  IgM  and  IgG  levels  in  G-1442  rose 
throughout the course of the illness, through day 20.  Contact G-1446 did not have measurable  
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IgG titers, and only registered a low IgM titer to Z.  Data are plotted as mean A450±SD, N=-2.  
The line between day 18 and 20 is dotted to reflect discontinuity on day 19. 
 
Figure 3. Comparison of LASV NP antigen detection by ELISA versus RNA quantification 
by qPCR 
RNA was prepared from serum samples as outlined in materials and methods.  RT-PCR followed 
by qPCR directed against the GPC gene was performed on days 7-18.  A 1:6 dilution series of 
Josiah strain seed stock was used as a standard to calculate the LASV RNA copy number per 
milliliter of serum.  PCR data were plotted on the second Y axis (LASV RNA copies/mL).  
Error-bars represent the SEM of two independent experiments.  NP Ag ELISA data was plotted 
on the first Y axis (A450) for trend comparison.  Trend lines for NP Ag ELISA (power) and qPCR 
(exponential), and associated R
2 values are indicated.  The limit of detection for antigen by NP 
Ag ELISA was day 9 (blue arrow), and day 11 for qPCR (red arrow). 
 
Figure 4. Comprehensive daily Piccolo metabolic panel analysis 
Metabolic indicators were measured in the serum of G-1442 daily after admission, through day 
20 (with the exception of day 19), using a Piccolo comprehensive metabolic panel disk array.  
Two Sierra Leonean normal controls were also analyzed for comparison (SLN004 and SLN022).  
Values were plotted alongside normal ranges for each metabolite (rose boxes), for reference.  G-
1442 presented with normal BUN, CRE, but elevated TBIL.  Analytes ALP, ALT, and AST were 
highly  elevated  upon  admission,  all  indicative  of  severe  liver  implication  in  this  LF  case.  
Metabolic  indicators  in  the  two  healthy  Sierra  Leonean  donors  were  within  normal  ranges.  
Hemoglobin levels were independently measured in G-1442 on days 7, 9-12, and 14-16 post- 
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onset of disease.  The day of stillbirth delivery is indicated in each panel by a dark red diamond 
(day 13). 
 
Figure 5. Serum cytokine levels analyzed by multiplex Flow Cytometry 
Data  generated with a  Human 11-Plex  Inflammatory Cytokine kit was quantified with Flow 
Cytomix Pro software, and plotted on linear scales.  G-1442 presented with elevated levels of 
TNF-β (Α.), IL-6, IL-8, IL-10, and notably IFN-γ (Β.), all of which decreased by the next day, 
following initial treatment with ribavirin (day 7, arrow).  Cytokine levels were also measured in 
normal Sierra Leonean controls, for comparison (LS004, LS022).  Significant changes in the 
cytokine profile were not noted following delivery of a stillbirth fetus (day 13, arrow). 
 
Figure 6. Phylogenetic analysis of LASV from patient G-1442. 
A  ca.  800bp  fragment  of  the  GPC  gene  was  sequenced  and  aligned  to  73  other  sequences 
available in the NCBI database. A Neighbor-joining tree using LASV Pinneo as an outgroup was 
created with 1,000 replicates of bootstrap and clades from different countries are displayed as 
cartoons.  Recent  LASV  isolates  from  the  Kenema  area  are  marked  in  blue.  The  scale  bar 
indicates 3% nucleotide divergence.  
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Additional Files 
Additional File 1 
Map  of  Sierra  Leone  and  expanded  view  of  relevant  localities  and  routes  travelled  by 
patient G-1442 
Maps  of  Sierra  Leone  outlining  Districts  (A)  and  Provinces  (B) 
[http://commons.wikimedia.org/wiki/Atlas_of_Sierra_Leone],  with  an  inset  map  (C) 
[http://maps.google.com] displaying the location of Mabineh 1 [red star], where the suspected LF 
case in the current report originated, and the four localities where the patient travelled to and 
from, with known dates noted: Waterloo (late Dec 2010), Masingbi (early Jan 2011), Tongo (Jan 
10, 2011), and Kenema (Jan 19, 2011).  The inbound routes travelled by the patient are indicated 
in dotted lines, and outbound ones in solid lines.  The bar represents 20 miles.   
 
Additional File 2  
Patient  G-1442  at  time  of  admission  presenting  with  haemoptysis,  facial  edema, 
gingivorrhagia 
Patient G-1442 presented with significant haemoptysis, facial edema, and gingivorrhagia, at the 
time of admission and medical assessment at the KGH LFW.  These symptoms persisted for 
several days after admission but resolved with ribavirin treatment. 
 
Additional Figure 3 
Vital signs for G-1442 during hospitalization at KGH LFW 
Core temperature (
oC) [green triangle], pulse [red circle], respiratory rate [blue diamond], and 
blood pressure purple [square = systolic, yellow square = diastolic] were measured at regular  
35 
 
intervals, usually every 4 hours at the onset, and every 12 hours at later times, throughout the 
hospitalization period.   
 
Additional Figure 4  
Additional Piccolo metabolites analyzed in G-1442 
Patient G-1442 presented with low serum Cl
- and albumin, normal K
+, Na
+, Ca
2+ (corrected for 
albumin levels), TCO2, and total protein levels.  Over the course of disease management the 
patient  developed  hyponatremia,  hypochloremia,  and  slight  hypokalemia.    Total  protein  and 
albumin  levels  remained  low  throughout.    Between  days  9  and  13  G-1442  developed 
hypercalcaemia, but then normalized.  Metabolic indicators in the two healthy Sierra Leonean 
donors all were within or near normal ranges.   
Additional Figure 5 
Table 1   
Urinalysis profile for patient G-1442 during the course of admission at the KGH LFW 
Urine  samples  were  collected  from  patient  G-1442  daily  (days  7-18)  and  tested  for  10 
metabolites as outlined in Methods.  The first day of ribavirin administration (7) and still birth 
delivery (13) are noted.  Abbreviations and codes: moderate (mod.); negative ( - ); positive ( + ); 
specific gravity (spec. gravity); 30 mg/dL protein in urine (30+); 300 mg/dL protein in urine 
(300+). 
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Additional Figure 6 
Table 2   
Metabolic, cytokine, LASV Ag, IgG, and IgM profiles for five patients who succumbed to 
LF at the KGH LFW in recent months, and in two healthy controls 
Thirteen metabolic indicators, 11 cytokines, LASV NP Ag, IgM, and IgG status were compared 
between 5 representative recent fatal cases of LF (G-1209, G-1220, G-1380, G-1401), including 
one previously characterized fatal late term pregnancy (G-1177), and two healthy volunteers 
(LS004, LS022).  Reported normal ranges for metabolic indicators (Abaxis, Inc.) and serum 
cytokine levels (Cambridge Biomedical [IL-1b, IL-10], BD Biosciences [IL-2, IL-4, IL-8, IL-
12p70], R&D Systems [IL-5, IL-6], Thermo Scientific [TNF-α], BioVendor [TNF-β, IFN-γ]) are 
shown in the rightmost corresponding columns.  Metabolic panel values are in SI units, and 
cytokine  levels  are  in  pg/mL.    ELISA  data  was  scored  as  positive  (+),  negative  (-),  or 
indeterminate (+/-), based on statistical comparison to positive and negative sera, and using a 
positive control serum dilution series. 
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